Romiplostim and Eltrombopag Beat Rituximab for Secondline Chronic Immune Thrombocytopenia Treatment
After frontline treatment with corticosteroids fails to elicit a response in patients with chronic immune thrombocytopenia (cITP), the choice between rituximab or thrombopoietin receptor...
How I Treat in Brief: Venous Thromboembolism in Sickle Cell Disease
Arun S. Shet, MD, from the NIH’s National Heart, Lung, and Blood Institute, and Ted Wun, MD, from UC Davis Comprehensive Cancer Center in...
Updated Romiplostim Label Supports Earlier Use in ITP
The U.S. Food and Drug Administration (FDA) granted approval to a supplemental Biologics License Application for romiplostim that updates the drug’s label to include...
Emicizumab Lowers Bleeding Rates in Children With Hemophilia A and Inhibitors
Once-weekly treatment with emicizumab prophylaxis led to low bleeding rates in children with hemophilia A and factor VIII (FVIII) inhibitors, with more than three-quarters...
Moderate-Intensity Endurance Training Improves Skeletal Microvasculature in Patients with Sickle Cell Disease
An endurance exercise training program of moderate intensity may reverse some of the microvascular deficits of skeletal microvasculature in patients with sickle cell disease...
The Fewer Transfusions, the Better for Newborns With Thrombocytopenia
Newborns with thrombocytopenia had a lower risk of death or bleeding if they received platelet transfusions according to a lower 25×109/L threshold rather than...
CRISPR Shows Early Benefit for Patients with Sickle Cell Disease and Beta Thalassemia
CRISPR Therapeutics and Vertex Pharmaceuticals have reported that the first two patients to receive the experimental treatment for sickle cell disease (SCD) and beta...
FDA Approves Crizanlizumab-tmca for Sickle Cell Disease
The U.S. Food and Drug Administration (FDA) has approved crizanlizumab-tmca, a monoclonal antibody against the P-selectin glycoprotein that is expressed on activated endothelial cells...
Heparin-Induced Thrombocytopenia Does Not Appear to Protect Against Major Bleeding
Patients with heparin-induced thrombocytopenia (HIT), a prothrombotic complication of heparin exposure, are believed to be protected against anticoagulant-associated bleeding, but results from a retrospective analysis...
Older Patients with iTTP Have Delayed Diagnosis and Higher Mortality Than Younger Counterparts
Older patients diagnosed with immune thrombotic thrombocytopenic purpura (iTTP) have worse short- and long-term mortality compared with younger patients and the general population, according...
Current Issue
December 2019, Volume 5, Issue 15
This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.
